Research Analysts Set Expectations for ABEO FY2025 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Abeona Therapeutics in a report issued on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of $1.23 for the year, up from their previous forecast of $1.22. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share.

Several other research firms have also recently weighed in on ABEO. Wall Street Zen cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Finally, Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a report on Monday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Abeona Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Abeona Therapeutics Trading Down 2.5%

Shares of ABEO stock opened at $5.01 on Wednesday. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.54. The stock has a market capitalization of $271.49 million, a P/E ratio of 4.07 and a beta of 1.13. The firm’s 50 day moving average is $5.14 and its 200 day moving average is $5.30.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, Director Christine Berni Silverstein sold 20,070 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $5.09, for a total transaction of $102,156.30. Following the completion of the sale, the director owned 137,722 shares of the company’s stock, valued at approximately $701,004.98. The trade was a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Eric Crombez sold 16,284 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $5.09, for a total value of $82,885.56. Following the completion of the sale, the director owned 63,456 shares of the company’s stock, valued at approximately $322,991.04. The trade was a 20.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 209,605 shares of company stock worth $1,101,300 over the last three months. 6.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Legato Capital Management LLC boosted its stake in Abeona Therapeutics by 21.0% in the 4th quarter. Legato Capital Management LLC now owns 13,180 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 2,290 shares during the period. Deutsche Bank AG boosted its position in shares of Abeona Therapeutics by 6.2% during the fourth quarter. Deutsche Bank AG now owns 39,368 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 2,303 shares during the last quarter. LPL Financial LLC boosted its position in shares of Abeona Therapeutics by 5.3% during the fourth quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 3,165 shares during the last quarter. Riverwater Partners LLC grew its stake in Abeona Therapeutics by 22.2% during the fourth quarter. Riverwater Partners LLC now owns 19,375 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 3,518 shares in the last quarter. Finally, Intech Investment Management LLC increased its holdings in Abeona Therapeutics by 19.6% in the 3rd quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 4,127 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.